Viatris Change in Accounts Payable 2010-2025 | VTRS
Viatris annual/quarterly change in accounts payable history and growth rate from 2010 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
- Viatris change in accounts payable for the quarter ending June 30, 2025 was $-0.190B, a 436.94% decline year-over-year.
- Viatris change in accounts payable for the twelve months ending June 30, 2025 was $-0.062B, a 106.9% decline year-over-year.
- Viatris annual change in accounts payable for 2024 was $0.036B, a 88.56% decline from 2023.
- Viatris annual change in accounts payable for 2023 was $0.315B, a 84.9% increase from 2022.
- Viatris annual change in accounts payable for 2022 was $0.17B, a 341.76% decline from 2021.
| Viatris Annual Change in Accounts Payable (Millions of US $) |
|
|---|---|
| 2024 | $36 |
| 2023 | $315 |
| 2022 | $170 |
| 2021 | $-70 |
| 2020 | $-83 |
| 2019 | $-96 |
| 2018 | $220 |
| 2017 | $14 |
| 2016 | $88 |
| 2015 | $132 |
| 2014 | $0 |
| 2013 | $137 |
| 2012 | $81 |
| 2011 | $134 |
| 2010 | $23 |
| 2009 | $4 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.452B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $151.946B | 28.18 |
| CVS Health (CVS) | United States | $90.013B | 11.19 |
| Elevance Health (ELV) | United States | $70.256B | 9.45 |
| Cencora (COR) | United States | $57.138B | 19.03 |
| DiDi Global (DIDIY) | China | $27.156B | 28.85 |
| Labcorp Holdings (LH) | United States | $22.916B | 18.22 |
| Natera (NTRA) | United States | $21.976B | 0.00 |
| BioMerieux (BMXMF) | France | $17.991B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $15.475B | 0.00 |
| ICON (ICLR) | Ireland | $14.507B | 13.96 |
| Medpace Holdings (MEDP) | United States | $12.983B | 34.36 |
| CochLear (CHEOY) | Australia | $12.561B | 0.00 |
| Solventum (SOLV) | United States | $12.531B | 12.93 |
| Revvity (RVTY) | United States | $10.611B | 18.69 |
| Caris Life Sciences,�Inc (CAI) | United States | $10.386B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $9.321B | 0.00 |
| Avantor (AVTR) | United States | $8.849B | 12.98 |
| Charles River Laboratories (CRL) | United States | $7.799B | 14.80 |
| HealthEquity (HQY) | United States | $7.777B | 34.06 |
| Bausch + Lomb (BLCO) | Canada | $5.172B | 34.79 |
| Sotera Health (SHC) | United States | $4.590B | 25.65 |
| BrightSpring Health Services (BTSG) | United States | $4.106B | 31.32 |
| Amplifon S.p.A (AMFPF) | Italy | $3.937B | 21.83 |
| GeneDx Holdings (WGS) | United States | $3.466B | 79.38 |
| Surgery Partners (SGRY) | United States | $2.974B | 37.42 |
| Alignment Healthcare (ALHC) | United States | $2.951B | 0.00 |
| Concentras Parent (CON) | United States | $2.944B | 18.67 |
| Organon (OGN) | United States | $2.407B | 2.62 |
| Premier (PINC) | United States | $2.158B | 20.01 |
| Progyny (PGNY) | United States | $1.955B | 41.35 |
| Ardent Health (ARDT) | United States | $1.849B | 7.14 |
| PACS (PACS) | United States | $1.804B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.623B | 27.47 |
| Pediatrix Medical (MD) | United States | $1.436B | 9.59 |
| Teladoc Health (TDOC) | United States | $1.297B | 0.00 |
| Omada Health (OMDA) | $1.171B | 0.00 | |
| Establishment Labs Holdings (ESTA) | $1.092B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.965B | 0.00 |
| Embecta (EMBC) | United States | $0.798B | 4.67 |
| AMN Healthcare Services Inc (AMN) | United States | $0.769B | 9.51 |
| CareDx (CDNA) | United States | $0.616B | 11.34 |
| Performant Healthcare (PHLT) | United States | $0.601B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.598B | 102.50 |
| Nutex Health (NUTX) | United States | $0.528B | 7.99 |
| Agilon Health (AGL) | United States | $0.518B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.477B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.475B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.466B | 7.00 |
| SBC Medicals (SBC) | United States | $0.424B | 9.30 |
| Enhabit (EHAB) | United States | $0.409B | 26.87 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.392B | 0.00 |
| So-Young (SY) | China | $0.376B | 0.00 |
| Oncology Institute (TOI) | United States | $0.341B | 0.00 |
| LifeMD (LFMD) | United States | $0.290B | 0.00 |
| Beauty Health (SKIN) | United States | $0.274B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.189B | 0.00 |
| DocGo (DCGO) | United States | $0.156B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.124B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.085B | 0.00 |
| KindlyMD (NAKA) | United States | $0.080B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 0.00 |
| Biodesix (BDSX) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.050B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.040B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.035B | 0.00 |
| ModivCare (MODV) | United States | $0.030B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.022B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.013B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.011B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.011B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.010B | 0.00 | |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |